Marvel Biosciences has obtained financial and strategic support from 5 Horizons Ventures to fund its upcoming Phase I clinical trial of MB-204, a drug candidate targeting autism spectrum disorder and related neurodevelopmental conditions. The partnership includes funding for 15% of clinical trial costs and collaboration with CRO Novotech, aiming to accelerate development while minimizing shareholder dilution. The Phase I trial, starting in Q2 2026, will assess MB-204's safety and pharmacokinetics, with plans to advance to Phase II/III for rare diseases like Rett syndrome and Fragile X syndrome. This support validates Marvel's clinical strategy and enhances its ability to develop treatments for unmet needs in neurological disorders.
The FTSE 100 index fell slightly, dragged down by mining stocks reacting to China's slower GDP growth of 4.3% in Q2, its weakest in three years. Despite this, oil prices remained steady amid US-Iran tensions. PayPal shares jumped over 14% following r...
The Goldman Sachs Future Tech Leaders Equity ETF (GTEK) has delivered a 48.9% return year-to-date, nearly doubling the 25% return of the Vanguard Information Technology ETF (VGT). Unlike VGT, which heavily invests in mega-cap tech giants like Nvidia,...
